Research map: Non-invasive multiparametric characterization of essential thrombocythemia, premyelofibrosis, and overt myelofibrosis

Back to the article

Papers in this map

  1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia · Daniel A. Arber · 2016 · 10386 citations · Cited by this paper
  2. Evolutionary considerations for risk stratification in TP53-variant myeloproliferative neoplasms · 2026 · Related
  3. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms · Joseph David Khoury · 2022 · 4220 citations · Cited by this paper
  4. Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry · 2026 · Related
  5. The NAFLD fibrosis score · Paul G. Angulo · 2007 · 3247 citations · Cited by this paper
  6. Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance · 2026 · Related
  7. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis · Laurent Sandrin · 2003 · 2749 citations · Cited by this paper
  8. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia · 2026 · Related
  9. Mutations and prognosis in primary myelofibrosis · Alessandro Maria Vannucchi · 2013 · 772 citations · Cited by this paper
  10. IKZF1N159S is associated with adverse outcomes in patients with myelodysplastic neoplasms · 2026 · Related
  11. Classification and Personalized Prognosis in Myeloproliferative Neoplasms · Jacob Grinfeld · 2018 · 643 citations · Cited by this paper
  12. Tumor molecular age acceleration is associated with early progression in diffuse large B-cell lymphoma · 2026 · Related
  13. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study · Ayalew Tefferi · 2011 · 609 citations · Cited by this paper
  14. Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry · 2026 · Related
  15. A novel panel of blood markers to assess the degree of liver fibrosis† · Paul Calès · 2005 · 560 citations · Cited by this paper
  16. Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms · 2026 · Related
  17. Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study · Tiziano Barbui · 2011 · 553 citations · Cited by this paper
  18. Stuck in traffic: CART cells targeting the tumor microenvironment in hematological malignancies, current advances and future perspectives · 2026 · Related
  19. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes · Bridget S. Wilkins · 2007 · 270 citations · Cited by this paper
  20. Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities · 2026 · Related
  21. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia · Giovanni Barosi · 2001 · 223 citations · Cited by this paper
  22. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification · Jürgen Thiele · 2011 · 181 citations · Cited by this paper
  23. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling · Daniel A.C. Fisher · 2019 · 148 citations · Cited by this paper
  24. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation · Sébastien Jacquelin · 2018 · 120 citations · Cited by this paper
  25. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms · Jacob Grinfeld · 2016 · 113 citations · Cited by this paper
  26. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis · Thomas Buhr · 2011 · 112 citations · Cited by this paper
  27. Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN · Hélène F.E. Gleitz · 2020 · 109 citations · Cited by this paper
  28. Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis · Giovanni Barosi · 2012 · 97 citations · Cited by this paper
  29. CXCL4 drives fibrosis by promoting several key cellular and molecular processes · Alsya J. Affandi · 2022 · 85 citations · Cited by this paper
  30. Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm · Shivam Rai · 2022 · 81 citations · Cited by this paper
  31. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis · Maud Brousseau · 2010 · 75 citations · Cited by this paper
  32. Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease · Georg Jeryczynski · 2017 · 67 citations · Cited by this paper
  33. Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms · Umberto Gianelli · 2013 · 62 citations · Cited by this paper
  34. Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia · Nina Friesgaard Øbro · 2020 · 61 citations · Cited by this paper
  35. World Health Organization‐defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations—The Danish experience · Ann Brinch Madelung · 2013 · 60 citations · Cited by this paper
  36. Follow‐up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients · Jüergen Thiele · 2002 · 59 citations · Cited by this paper
  37. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm · Mohammed Ferdous‐Ur Rahman · 2022 · 56 citations · Cited by this paper
  38. Clinical correlates of splenic histopathology and splenic karyotype in myelofibrosis with myeloid metaplasia · Ruben A. Mesa · 2001 · 49 citations · Cited by this paper
  39. Reproducibility of Histologic Classification in Nonfibrotic Myeloproliferative Neoplasia · Suzanne M. Koopmans · 2011 · 35 citations · Cited by this paper

Source: OpenAlex (CC0)